Cancer / Oncology/Hodgkin lymphoma
Hematologic · type
Hodgkin lymphoma
Clinical / Scientific
Classical Hodgkin lymphoma is a rare-tumour-cell, abundant-inflammatory-niche disease: Reed–Sternberg cells with NF-κB and JAK/STAT activation and PD-L1 amplification. Checkpoint blockade is established in relapsed settings. The biology is microenvironment-dominant.
Core Biological Drivers
NF-κB / JAK-STAT
RS-cell survival.
PD-L1 amplification
9p24.1 in many cases.
Inflammatory niche
Eosinophils, Tregs, macrophages.
Key Pathways
Scientific explanation
NF-κB factors link inflammatory cytokines and innate sensors to survival, production and sometimes therapy resistance.
Scientific explanation
receptors signal through JAKs to STATs. in particular supports survival, invasion and inflammatory gene programmes in many solid and hematologic tumours.
Scientific explanation
PD-1 on T cells engaging PD-L1/PD-L2 restrains cytotoxic function. Tumour or myeloid PD-L1 is a canonical adaptive immune-evasion axis.
Scientific explanation
CTLA-4 competes with CD28 for B7 ligands, restraining priming of T cells mainly in lymphoid tissues and Tregs.
Scientific explanation
Tumours recruit Tregs, MDSCs and M2-like macrophages, and secrete TGF-β, IL-10, adenosine and IDO-related metabolites to blunt effector immunity.
Scientific explanation
Intrinsic and extrinsic apoptotic programmes remove damaged cells. Evasion of is a hallmark, via BCL-2 family imbalance, death- decoys, or p53 loss.
Pathway Convergence
Target → pathway → downstream effect → biological consequence. Shared intersections are mechanistic maps, not protocols.
Inflammatory survival
Chronic cytokine tone activates NF-κB and STAT3 transcriptional programmes that favour survival, invasion and sometimes immune evasion.
Metabolic Vulnerabilities
Aerobic supports ATP, biomass and acidification even when oxygen is available. Extent varies by tumour and remains a vulnerability hypothesis rather than a uniform target.
Tumor Microenvironment
Tumour-associated macrophages and myeloid-derived suppressor cells secrete cytokines that support invasion and blunt cytotoxic T cells.
The inflammatory milieu is tumour-supportive rather than purely defensive.
Metastasis Module
Leukemias and related neoplasms disseminate by trafficking rather than classical -driven carcinoma . Marrow, blood and lymphoid niches dominate.
Resistance Biology
Checkpoint resistance via alternative immune suppression.
Cancer Stemness
Wnt, Notch, Hedgehog, ALDH and CD44-associated programmes can mark stem-like fractions with quiescence and therapy tolerance. These markers are not interchangeable across tumour types.
Mechanism-Based Adjunctive Strategies
Compounds appear only where a mechanistic overlap exists for this cancer. Evidence tiers are not equivalent. Nothing here is a treatment recommendation.
Curcumin
Target / Mechanism
Polyphenol with promiscuous in-vitro NF-κB, and ROS effects. Bioavailability is poor; dish activity does not establish clinical anticancer efficacy.
Cancer relevance
In-vitro NF-κB/ effects are frequent. Poor bioavailability and absence of robust clinical anticancer efficacy keep this pathway-level.
Inflammatory-signalling dish models. Convergence: NF-κB, JAK/STAT.
Celecoxib
Target / Mechanism
Selective -2 reducing PGE2. Relevant to -associated epithelial neoplasia; cardiovascular risk and lack of broad anticancer approval constrain interpretation.
Cancer relevance
-2/PGE2 biology is relevant in some epithelial neoplasias. Cardiovascular risk and lack of broad anticancer approval apply. Do not equate polyp or biomarker studies with tumour cure.
Inflammation-associated epithelial neoplasia research. Convergence: COX / inflammatory signalling, Angiogenesis.
Omega-3 fatty acids
Target / Mechanism
EPA/DHA alter eicosanoid balance and membrane signalling. Cachexia and hypotheses exist; they are not cytotoxic oncology drugs.
Cancer relevance
Eicosanoid rebalancing and cachexia/ research. Not cytotoxic oncology.
Inflammation / cachexia supportive research. Convergence: COX / inflammatory signalling, Immune suppression.
Beta-glucans / medicinal-mushroom polysaccharides
Target / Mechanism
β-glucans can engage Dectin-1 and complement pathways, modulating innate immunity in models and some adjunctive clinical settings. They are not tumour-selective cytotoxics.
Cancer relevance
Innate-immune engagement via Dectin-1-related biology. Adjunctive immunomodulation is not tumour-selective cytotoxicity.
Innate-immune adjunctive research. Convergence: Immune suppression.
Research Context
- Checkpoints. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. https://doi.org/10.1038/nrc3239
- NF-κB. Karin M. NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1(5):a000141. https://doi.org/10.1101/cshperspect.a000141
- STAT3. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736-746. https://doi.org/10.1038/nrc3818
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.